Physician profile
Howard Hampel
NPI 1700825635
$6,007.55
in general payments reported to CMS, 2019-2025
36 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $172 · 2021: $163 · 2022: $767 · 2023: $1,359 · 2024: $1,394 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,940 · Education: $99.64 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.80 |
| Education | $99.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,695.18 | 2019-2025 | |
| Janssen Biotech, INC. | $885.61 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $412.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.19 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $301.49 | 2019-2025 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $293.06 | 2022-2024 | Tremfya, Stelara |
| Genzyme Corporation | $257.63 | 2022-2025 | |
| Qol Medical, LLC | $256.45 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $161.56 | 2019-2023 | Rebyota, Cimzia |
| Lilly USA, LLC | $141.30 | 2024-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $140.28 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $113.10 | 2023 | Zeposia |
| Celgene Corporation | $86.85 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $83.41 | 2019-2024 | |
| Braintree Laboratories, INC. | $73.84 | 2019-2024 | Sutab, Suflave |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.83 | 2022-2024 | Dupixent |
| Laborie Medical Technologies Corp. | $57.72 | 2023 | |
| Daiichi Sankyo INC. | $56.43 | 2019-2023 | Injectafer |
| Novo Nordisk INC | $55.42 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $54.00 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $50.82 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $49.81 | 2024-2025 | Vowst |
| Gilead Sciences, INC. | $46.59 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $38.33 | 2025 | Voquezna |
| Ucb, INC. | $37.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.94 | 2023-2024 | Cyltezo |
| Ethicon US, LLC | $28.48 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.64 | 2022 | |
| Evoke Pharma, INC. | $16.91 | 2025 | |
| Redhill Biopharma INC. | $16.76 | 2020 | |
| Pharmacosmos Therapeutics INC. | $15.44 | 2025 | Monoferric |
| Shire North American Group INC | $14.22 | 2019 | |
| Organon LLC | $13.93 | 2023 | Renflexis |
| Merck Sharp & Dohme LLC | $12.33 | 2019 | |
| Concordia Pharmaceuticals INC. | $12.10 | 2019 | |
| Allergan, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Hampel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.